OncLive TV

Deepu Madduri, MD, assistant professor, Mount Sinai Hospital, discusses treatment after CAR T-cell therapy in patients with myeloma.

Daniel Vaena, MD, medical oncologist and hematologist, West Cancer Center, discusses the importance of risk stratification in prostate cancer.

Aditya Bardia, MD, MPH, director of Precision Medicine at the Center for Breast Cancer, Massachusetts General Hospital Cancer Center, Harvard Medical School, discusses potential concerns regarding the use of biosimilars in the breast cancer space.

Heather Greene, a nurse practitioner at West Cancer Center, discusses common treatment-related toxicities in metastatic renal cell carcinoma (RCC).

Joshua K. Sabari, MD, assistant professor of medicine, NYU Langone's Perlmutter Cancer Center, compares liquid and tissue biopsies for the treatment of patients with advanced non–small cell lung cancer.

Bradley G. Somer, MD, associate professor of hematology/oncology, head of strategic expansion/development, University of Tennessee West Cancer Center, discusses the potential for immunotherapy combinations in metastatic renal cell carcinoma.

Patrick I. Borgen, MD, chair, Department of Surgery, director, Breast Cancer, Maimonides Medical Center, discusses the potential global impact of biosimilars in oncology.

Jay H. Fowke, PhD, MPH, MS, chief, Division of Epidemiology, professor of preventive medicine, University of Tennessee Health Science Center, discusses ways to overcome racial disparity in prostate cancer.

Leora Horn, MD, associate professor of medicine (hematology and oncology), assistant director, educator development program, clinical director, Thoracic Oncology, medical oncologist, Vanderbilt-Ingram Medical Center, discusses the FDA approval of atezolizumab (Tecentriq) for use in combination with bevacizumab (Avastin), carboplatin, and paclitaxel for the first-line treatment of patients with metastatic nonsquamous non–small cell lung cancer.

Michael Pulsipher, MD, director of cellular therapy and stem cell transplantation, professor of pediatrics, USC Keck School of Medicine, discusses the role of MRD testing in pediatric patients treated with CAR T-cell therapy.

Asim Amin, MD, PhD, director of immunotherapy, Levine Cancer Institute, discusses the rationale for the pivotal CheckMate-214 trial in advanced renal cell carcinoma.

Mark D. Pegram, MD, Susy Yuan-Huey Hung Professor, co-director, Stanford’s Molecular Therapeutics Program, director, Breast Cancer Oncology Program, Stanford Women’s Cancer Center, discusses the manufacturing process of biosimilars.

Hendrik-Tobias Arkenau, MD, PhD, medical director, Sarah Cannon Research Institute UK, discusses the potential of immunotherapy in gastric cancer.

Kristen N. Ganjoo, MD, associate professor of medicine, Stanford University Medical Center, Stanford Medicine, discusses the risks of morcellation.

John Strickler, MD, assistant professor of medicine, Duke University School of Medicine, gastrointestinal oncologist, Duke Cancer Institute, discusses improvements in the treatment of metastatic colorectal cancer.

Alexander E. Perl, MD, associate professor of medicine, University of Pennsylvania, Perelman School of Medicine, discusses the promise of CAR T cells in the treatment of pediatric leukemia.

Robert J. Cerfolio, MD, MBA, director, Lung Cancer Center, chief, clinical thoracic surgery, discusses the impact of minimally invasive surgery in the management of non–small cell lung cancer.

Brian D. Crompton, MD, physician, Pediatric Hematology/Oncology, Dana-Farber Cancer Institute, assistant professor of pediatrics, Harvard Medical School, discusses the potential of liquid biopsies in the treatment of pediatric patients with sarcoma.

Adam M. Brufsky, MD, PhD, professor of medicine, associate chief, Division of Hematology/Oncology, co-director, Comprehensive Breast Cancer Center, associate director, Clinical Investigation, University of Pittsburgh, addresses biosimilar skepticism.

Ajai Chari, MD, associate professor of medicine, Hematology and Medical Oncology, Mount Sinai Hospital, discusses carfilzomib (Kyprolis) dosing in the treatment of patients with multiple myeloma.

Santhosh Upadhyaya, MD, neuro-oncologist, St. Jude Children’s Research Hospital, discusses risk factors for developing pediatric ependymoma.

Thomas G. Martin, MD, clinical professor of medicine, Adult Leukemia and Bone Marrow Transplantation Program, associate director, Myeloma Program, University of California, San Francisco (UCSF); co-leader, Hematopoietic Malignancies Program, Helen Diller Family Comprehensive Cancer Center, discusses minimal residual disease (MRD) status in multiple myeloma.

Susan F. Slovin, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses androgen receptor therapy (ADT)-associated cardiac complications in prostate cancer.

Erlene Seymour, MD, assistant professor of medicine, Karmanos Cancer Institute, Wayne State University, discusses the role of ibrutinib in the treatment of patients with chronic lymphocytic leukemia.

Patrick I. Borgen, MD, chair, Department of Surgery, director, Breast Cancer, Maimonides Medical Center, discusses the equivalence of biosimilars in oncology.

Julie R. Brahmer, MD, associate professor of oncology, co-director of the Upper Aerodigestive Department, Bloomberg Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine, discusses the role of immunotherapy in the treatment of patients with metastatic non–small cell lung cancer (NSCLC).

Adam M. Brufsky, MD, PhD, associate director, Clinical Investigation, University of Pittsburgh, discusses genomic assays for breast cancer.

Mark D. Pegram, MD, Susy Yuan-Huey Hung Professor, co-director, Stanford’s Molecular Therapeutics Program, director, Breast Cancer Oncology Program, Stanford Women’s Cancer Center, discusses projections of cost reductions with biosimilars.

Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, Jerome and Nancy Kohlberg Associate Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses frontline trials of immunotherapy in renal cell carcinoma.

Charalambos (Babis) Andreadis, MD, MSCE, associate professor of clinical medicine, Department of Medicine, University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses the treatment of patients with relapsed diffuse large B-cell lymphoma.